Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.67 |
| ▸ | MAPT | P10636 | 10/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.58 |
| ▸ | HTT | P42858 | 4/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30272141 | 1.00 | LMNA (0.67) | LMNAMAPTALDH1A1HTTPKM | |
| SCHEMBL3680356 | 0.80 | LMNA (0.67) | LMNAMAPTALDH1A1HTTPKM | |
| SCHEMBL17844954 | 0.80 | LMNA (1.00) | LMNAMAPTALDH1A1HTTPKM | |
| SCHEMBL21645618 | 0.80 | LMNA (0.67) | LMNAMAPTALDH1A1HTTPKM | |
| SCHEMBL5138522 | 0.80 | LMNA (0.67) | LMNAMAPTALDH1A1HTTPKM | |
| SCHEMBL28271364 | 0.77 | MAPT (0.49) | LMNAMAPTALDH1A1HTTPKM | |
| SCHEMBL3680354 | 0.77 | LMNA (0.62) | LMNAMAPTALDH1A1HTTPKM | |
| SCHEMBL10615652 | 0.76 | MAPT (1.00) | LMNAMAPTALDH1A1HTTPKM | |
| SCHEMBL2540914 | 0.76 | ALDH1A1 (0.53) | LMNAMAPTALDH1A1HTTKMT2A | |
| SCHEMBL18153335 | 0.74 | LMNA (0.59) | LMNAMAPTALDH1A1HTTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023027630-A9 | A FLOW REACTOR, METHODS OF FABRICATION AND REACTIONS THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-07-27 | — | — | WO | claimed |
| WO-2023027630-A2 | A FLOW REACTOR, METHODS OF FABRICATION AND REACTIONS THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-03-02 | — | — | WO | claimed |
| US-12486293-B2 | Chirality sensing with molecular click chemistry probes | GEORGETOWN UNIVERSITY (US) | 2025-12-02 | — | — | US | disclosed |
| US-20240092800-A1 | USP13 INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2024-03-21 | — | — | US | disclosed |
| WO-2023027630-A9 | A FLOW REACTOR, METHODS OF FABRICATION AND REACTIONS THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023027630-A2 | A FLOW REACTOR, METHODS OF FABRICATION AND REACTIONS THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-03-02 | — | — | WO | disclosed |
| US-20220380395-A1 | CHIRALITY SENSING WITH MOLECULAR CLICK CHEMISTRY PROBES | GEORGETOWN UNIVERSITY | 2022-12-01 | — | — | US | disclosed |
| EP-1807440-B1 | NOVOBIOCIN ANALOGUES AS ANTICANCER AGENTS | UNIV KANSAS (US) | 2020-02-19 | — | — | EP | disclosed |
| WO-2020028396-A1 | CHIRALITY SENSING WITH MOLECULAR CLICK CHEMISTRY PROBES | GEORGETOWN UNIVERSITY (US) | 2020-02-06 | — | — | WO | disclosed |
| EP-2438078-B1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | UNIV KANSAS (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | CORNELL UNIVERSITY | 2016-06-16 | — | — | US | disclosed |
| US-7608594-B2 | Novobiocin analogues as anticancer agents | UNIVERSITY OF KANSAS (US) | 2009-10-27 | — | — | US | disclosed |
| US-20090187014-A1 | Novobiocin Analogues | UNIVERSITY OF KANSAS | 2009-07-23 | — | — | US | disclosed |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-25 | — | — | US | disclosed |
| EP-2049511-A1 | USE OF COUMARIN DERIVATIVES IN ANTIFUNGAL THERAPY | Novabiotics Limited (GB) | 2009-04-22 | — | — | EP | disclosed |
| WO-2007141513-A1 | USE OF COUMARIN DERIVATIVES IN ANTIFUNGAL THERAPY | NOVABIOTICS LIMITED (GB) | 2007-12-13 | — | — | WO | disclosed |
| US-20070270452-A1 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-22 | — | — | US | disclosed |
| EP-1807440-A2 | NOVOBIOCIN ANALOGUES AS ANTICANCER AGENTS | The University of Kansas (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20060199776-A1 | Novobiocin analogues as anticancer agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-09-07 | — | — | US | disclosed |
| WO-2006050501-A2 | NOVOBIOCIN ANALOGUES AS ANTICANCER AGENTS | UNIVERSITY OF KANSAS (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380395-A1 | CHIRALITY SENSING WITH MOLECULAR CLICK CHEMISTRY PROBES | PTMS, NISCH, CHAMP1 | LMNA 2928/4885MAPT 4815/4885ALDH1A1 1668/4885 |
| US-20240092800-A1 | USP13 INHIBITORS AND METHODS OF USE THEREOF | USP13, USP3, USP1 | LMNA 2192/4885MAPT 290/4885ALDH1A1 2241/4885 |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | HSP90AB1, HSP90B1, HSP90AB2P | LMNA 4561/4885MAPT 1221/4885ALDH1A1 3407/4885 |
| US-20070270452-A1 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | SSB, IAPP, NLN | LMNA 1526/4885MAPT 272/4885ALDH1A1 4309/4885 |
| US-20060199776-A1 | Novobiocin analogues as anticancer agents | HSP90B1, HSP90AB2P, HSP90AB1 | LMNA 2952/4885MAPT 1100/4885ALDH1A1 2718/4885 |
| US-12486293-B2 | Chirality sensing with molecular click chemistry probes | PTMS, NISCH, CHAMP1 | LMNA 2928/4885MAPT 4815/4885ALDH1A1 1668/4885 |
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | BCL6, BCL6B, BAZ2A | LMNA 3890/4885MAPT 2263/4885ALDH1A1 4832/4885 |
| US-20090187014-A1 | Novobiocin Analogues | SSB, SSBP1, BTD | LMNA 1560/4885MAPT 342/4885ALDH1A1 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.